Skip to main content

Table 1 Main basal risk factors for MACE in the cardiovascular outcome trials testing the effect of SGLT2 inhibition in type 2 diabetes

From: Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney

Trial
Sample size
SGLT2-IAge, yearsSmokers,  % ptsBMI, kg/m2Systolic BP, mmHgHbA1c,  %LDL-C, mg/dLACVD,  % ptseGFR, mL/min/1.73 m2eGFR < 60,  % ptsAnti-RAS,  % ptsStatin,  % pts
EMPA-REG n = 7021Empa63 ± 913.031 ± 5135 ± 178.1 ± 0.986 ± 368974 ± 2226.081.077.4
CANVAS n = 10,142Cana63 ± 817.832 ± 6137 ± 168.2 ± 0.989 ± 357277 ± 2125.080.274.7
DECLARE n = 17,160Dapa64 ± 714.532 ± 6135 ± 158.3 ± 1.289 ± 354185 ± 167.081.374.9
CREDENCE n = 4401Cana63 ± 914.531 ± 6140 ± 168.3 ± 1.396 ± 416956 ± 1859.899.969.8
  1. MACE: major adverse cardiovascular evets, that is, cardiovascular death, myocardial infarction, or ischemic stroke; BP: blood pressure; LDL-C: LDL cholesterol; ACVD: atherosclerotic cardiovascular disease; Anti-RAS: inhibitors of renin angiotensin system; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate